Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT02045264
First received: January 13, 2014
Last updated: January 6, 2015
Last verified: January 2015
  Purpose

This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.


Condition Intervention Phase
Hereditary Angioedema (HAE)
Drug: Icatibant (30 mg)
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

Resource links provided by NLM:


Further study details as provided by Shire:

Primary Outcome Measures:
  • Peak Plasma Concentration (Cmax) of Icatibant and Metabolites [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: No ]
    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

  • Time to Peak Plasma Concentration (Tmax) of Icatibant and Metabolites [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: No ]
    Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.

  • Drug Concentration Half-Life (T1/2) of Icatibant and Metabolites [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: No ]
    The time it takes for the blood plasma concentration of a substance to halve.

  • Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Icatibant and Metabolites [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: No ]
    AUCinf is the area under the plasma concentration versus time curve extrapolated from time 0 to infinity, calculated using the observed value of the last non-zero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

  • Total Body Clearance (CL/F) of Icatibant [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: No ]
    The rate at which a drug is removed from the body.

  • Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Icatibant and Metabolites [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: No ]
    AUC0-t is the area under the plasma concentration versus time curve extrapolated from time 0 to to the last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.


Secondary Outcome Measures:
  • The Total Number of Treatment-Emergent Adverse Events [ Time Frame: TEAEs were collected after the single dose of icatibant until follow up, 5-7 days after icatibant administration ] [ Designated as safety issue: Yes ]
    Treatment-emergent adverse events (TEAEs) were those that started after the single dose of icatibant.

  • The Percentage of Subjects With Any Injection Site Reactions. [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: Yes ]
  • Safety Evaluation Measured by Percentage of Subjects With Not Clinically Significant Abnormalities in ECG Results [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Diastolic Blood Pressure [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Systolic Blood Pressure [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Pulse Rate [ Time Frame: Over 48 hours post-dose ] [ Designated as safety issue: Yes ]

Enrollment: 12
Study Start Date: February 2014
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Icatibant (30 mg)
30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area
Drug: Icatibant (30 mg)
On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
Other Name: Firazyr

Detailed Description:

Icatibant has been studied for the treatment of acute attacks of hereditary angioedema (HAE), an autosomal dominant disorder characterized by recurrent and self-limiting episodes of edema of the skin, larynx, and gastrointestinal tract. The most serious manifestation of an HAE attack is laryngeal edema, causing obstruction of the upper airways that may lead to death by asphyxiation if undiagnosed and/or untreated.

Icatibant has been approved in over 40 countries around the world including the United States (US) and Europe for the treatment of acute attacks of hereditary angioedema (HAE) in adults. This study is being conducted to evaluate the safety and tolerability of icatibant in a Japanese population and to evaluate whether race/ethnicity impacts the pharmacokinetics of icatibant after single subcutaneous injection.

This is an open-label, single-arm study that will enroll at least 12 Japanese subjects (in order to have 12 subjects complete the study), age 18-55 years inclusive. All subjects will receive a single subcutaneous injection of 30mg icatibant. The study will be conducted at 1 site in the US. The study will consist of a Screening Period, a Treatment Period, and a Follow-Up Period.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male and female volunteers, 18 to 55 years of age, inclusive; healthy status defined as absence of clinically significant findings in medical history or screening assessments
  2. Japanese; defined as born in Japan, lived outside of Japan for no more than 10 years, and having Japanese parents and Japanese maternal and paternal grandparents
  3. Body mass index of 18 to 28 kg/m2, inclusive

Exclusion Criteria:

  1. History of, or current, clinically significant disease and/or abnormalities
  2. Smoking habit in excess of 5 cigarettes per day or the equivalent within 30 days of Day 1 or inability to refrain from smoking during the study confinement period
  3. Subject has current abnormal thyroid function, as defined as abnormal screening thyroid stimulating hormone (TSH) and free thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 12 weeks is permitted
  4. History of drug allergy or other allergy that, in the opinion of the investigator, contraindicates participation
  5. Male subjects who consume more than 21 units of alcohol per week or 3 units per day. Female subjects who consume more than 14 units of alcohol per week or 2 units per day. (1 alcohol unit =1 beer or =1 wine (5oz/150mL) or =1 liquor (1.5oz/40mL) or =0.75oz alcohol)
  6. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (1 caffeine unit is contained in the following items: one 6oz (180mL) cup of coffee, two 12oz (360mL) cans of cola, one 12oz cup of tea, three 1oz (85g) chocolate bars. Decaffeinated coffee, tea, or cola are not considered to contain caffeine)
  7. Current use of any medication (including over-the-counter, herbal, or homeopathic preparations) with the exception of female hormonal replacement therapy or hormonal contraceptives. Occasional use of over-the-counter doses of ibuprofen or acetaminophen for minor self-limited pain (eg, headaches) is also acceptable. Current use is defined as use within 7 days of the first dose of investigational product\
  8. Pregnant or lactating females
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02045264

Locations
United States, California
PAREXEL
Glendale, California, United States, 91206
Sponsors and Collaborators
Shire
Investigators
Study Director: Alan Kimura, MD, PhD Shire
  More Information

No publications provided

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT02045264     History of Changes
Other Study ID Numbers: SHP-FIR-101
Study First Received: January 13, 2014
Results First Received: January 6, 2015
Last Updated: January 6, 2015
Health Authority: Japan: Ministry of Health, Labor and Welfare
Japan: Pharmaceuticals and Medical Devices Agency
United States: Food and Drug Administration

Keywords provided by Shire:
Firazyr
Angioedema
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Urticaria
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Genetic Diseases, Inborn
Icatibant
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents

Additional relevant MeSH terms:
Angioedema
Angioedemas, Hereditary
Cardiovascular Diseases
Genetic Diseases, Inborn
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Skin Diseases
Skin Diseases, Vascular
Urticaria
Vascular Diseases
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Icatibant
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-Antagonists
Analgesics
Analgesics, Non-Narcotic
Antirheumatic Agents
Central Nervous System Agents
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 23, 2015